Chinese cancer immunotherapy company Shanghai Cell Therapy Group Co. has raised RMB275 million (US$39.60 million) in series C1 round of financing from private equity firm China Industrial Asset Management Limited.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!
Register NowAlready have an account or paid subscription? Log in
